Blueprint Medicines to Present Preliminary Data from Ongoing Phase 1 Clinical Trials for BLU-285 and BLU-554 at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass., Nov. 15, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that preliminary data from the Phase 1 clinical trials evaluating BLU-285 for the treatment of advanced GIST and BLU-554 for the treatment of advanced HCC will be presented at the 28^th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Munich, Germany, November 29 – December 2, 2016.

The accepted abstracts are listed below. Preliminary data from the Phase 1 clinical trial evaluating BLU-285 for the treatment of unresectable PDGFRα-driven GIST and treatment-resistant KIT-driven GIST will be reported in a late-breaking oral presentation. As a result, the abstract and data will remain embargoed until December 1, 2016 at 7:00 a.m. CET (1:00 a.m. ET). The abstract from the Phase 1 clinical trial for BLU-554 for the treatment of advanced HCC is now available online on the conference website at: http://www.ecco-org.eu/Events/ENA2016.

Late-Breaking Oral Presentation:

Date & Time: Thursday, December 1, 2016 at 4:00 p.m. CET (10:00 a.m. ET)
Session Title: Proffered Paper Session
Abstract Number: 6LBA
Presentation Title: Preliminary Safety and Activity in a First-in-Human Phase 1 Study of BLU-285, a Potent, Highly-Selective Inhibitor of KIT and PDGFRα Activation Loop Mutants in Advanced Gastrointestinal Stromal Tumor (GIST)
Location: ICM - International Congress Center Munich, Room 14

Poster Presentation:

Date & Time: Tuesday, November 29, 2016 from 11:45 a.m. – 6:30 p.m. CET (5:45 a.m. – 12:30 p.m. ET)
Session Title: Molecular Targeted Agents I
Abstract Number: 105A
Presentation Title: First-in-Human Study of BLU-554, a Potent, Highly-Selective FGFR4 Inhibitor Designed for Hepatocellular Carcinoma (HCC) with FGFR4 Pathway Activation  
Location: ICM – International Congress Center Munich, Poster Area, Poster Number P076A

Conference Call information

Blueprint Medicines will host a conference call and webcast on Thursday, December 1, 2016 at 12:30 p.m. ET to discuss the preliminary clinical data for BLU-285 in GIST and BLU-554 in HCC. To participate in the conference call, please dial 1-855-728-4793 (domestic) or 1-503-343-6666 (international) and refer to conference ID 10770449. A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. A replay of the webcast will be available approximately two hours after the conference call and will be available for 30 days following the call.

About Blueprint Medicines

Blueprint Medicines is developing a new generation of targeted kinase medicines to improve the lives of patients with genomically defined diseases. The Company's approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing three programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma and systemic mastocytosis, as well as multiple programs in research and preclinical development. For more information, please visit www.blueprintmedicines.com.

Logo - http://photos.prnewswire.com/prnh/20150605/221118LOGO

SOURCE Blueprint Medicines

Related Links

http://www.blueprintmedicines.com